Menu
Back to Journals » Cancer Management and Research » Volume 5
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
Authors Araujo J, Trudel G, Paliwal P
Received 15 December 2012
Accepted for publication 31 January 2013
Published 9 March 2013 Volume 2013:5 Pages 25—30
DOI https://doi.org/10.2147/CMAR.S41667
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
John C Araujo,1 Geralyn C Trudel,2 Prashni Paliwal3
1Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Bristol-Myers Squibb, Montreal, Quebec, Canada; 3Bristol-Myers Squibb, Wallingford, CT, USA
Abstract: Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-androgen targeting therapies. This article describes the preclinical rationale for the use of combination dasatinib and docetaxel therapy in mCRPC, and highlights the results of a phase I–II trial in which 46 patients with mCRPC, treated with a regimen of dasatinib and docetaxel, demonstrated improvements in bone scans, high rates of soft tissue responses, and modulation of markers of bone turnover. This brief report discusses in detail follow-up data on two patients who remain alive after >2.5 years on dasatinib single-agent therapy after discontinuing docetaxel treatment.
Keywords: case study, dasatinib, docetaxel, prostate cancer, targeted therapy
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.